Hyton

Hyton (Hyton) is indicated in Attention Deficit Hyperactivity Disorder (ADHD). Because of its association with life threatening hepatic failure, Hyton (Hyton) should not ordinarily be considered as first line therapy for ADHD.

Hyton (Hyton) therapy should be proof of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

Hyton belongs to the group of medicines called central nervous system (CNS) stimulants. It is used to treat children with attention-deficit hyperactivity disorder (ADHD).

Hyton increases attention and decreases restlessness in children who are overactive, cannot concentrate for very long or are easily distracted, and are emotionally unstable. Hyton is used as part of a total treatment program that also includes social, educational, and psychological treatment.

Rarely, Hyton has caused serious liver problems. You and your doctor should talk about the good Hyton will do as well as the risks of using it. In addition, you will be asked to sign an informed consent form stating that you understand and agree to accept the risk of liver problems.

Hyton is available only with your doctor's prescription.

Applies to the following strengths: 18.75 mg; 37.5 mg; 75 mg

Usual Adult Dose for:

• Attention Deficit Disorder

Usual Pediatric Dose for:

• Attention Deficit Disorder

Additional dosage information:

• Renal Dose Adjustments
• Liver Dose Adjustments
• Dose Adjustments
• Precautions
• Dialysis
• Other Comments

Usual Adult Dose for Attention Deficit Disorder

Hyton was voluntarily withdrawn from the U.S. market by the manufacturers in October, 2005 due to a conclusion by the FDA that the overall risk of liver toxicity from Hyton products outweighs the benefits of this drug. The following dosage information applies to when the drug was available in the U.S.

Initial dose: 37.5 mg orally every morning.

Maintenance dose: May increase by 18.75 mg a day at one week intervals, up to a maximum of 112.5 mg/day. The effective dose range is 56.25 to 75 mg for most patients.

Usual Pediatric Dose for Attention Deficit Disorder

Hyton was voluntarily withdrawn from the U.S. market by the manufacturers in October, 2005 due to a conclusion by the FDA that the overall risk of liver toxicity from Hyton products outweighs the benefits of this drug. The following dosage information applies to when the drug was available in the U.S.

<6 years: Safety and efficacy have not been established.

>=6 years:

Initial dose: 37.5 mg orally every morning.

Maintenance dose: May increase by 18.75 mg a day at one week intervals, up to a maximum of 112.5 mg/day. The effective dose range is 56.25 to 75 mg for most patients.

Renal Dose Adjustments

Hyton should be administered with caution to patients with significantly impaired renal function.

Liver Dose Adjustments

Because of its association with life threatening hepatic failure, Hyton should not ordinarily be considered as first line drug therapy for ADHD. Treatment with Hyton should be initiated only in individuals without liver disease and with normal baseline liver function tests. It is not clear if baseline and periodic liver function testing are predictive of these instances of acute liver failure; however it is generally believed that early detection of drug-induced hepatic injury along with immediate withdrawal of the suspect drug enhances the likelihood for recovery.

The following liver monitoring program is recommended: Serum ALT (SGPT) levels should be determined at baseline, and every two weeks thereafter. If Hyton therapy is discontinued and then restarted, liver function test monitoring should be done at baseline and reinitiated at the frequency above.

Hyton should be discontinued if serum ALT (SGPT) is increased to a clinically significant level, or any increase >= 2 times the upper limit of normal, or if clinical signs and symptoms suggest liver failure.

Dose Adjustments

Clinical improvement with Hyton is gradual. Using the recommended schedule of dosage titration, significant benefit may not be evident until the third or fourth week of drug administration. Because Hyton provides an observable symptomatic benefit, patients who fail to show substantial clinical benefit within 3 weeks of completing dose titration, should be withdrawn from Hyton therapy.

Precautions

Decrements in the predicted growth (i.e., weight gain and/or height) rate have been reported with the long-term use of stimulants in children. Therefore, patients requiring long-term therapy should be carefully monitored.

Clinical experience suggests that in psychotic children, administration of Hyton may exacerbate symptoms of behavior disturbance and thought disorder.

Dialysis

Data not available.

Other Comments

Hyton therapy should be part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer

More about Hyton

• Hyton Side Effects
• During Pregnancy
• Drug Images
• Drug Interactions
• Support Group
• 11 Reviews
• Drug class: CNS stimulants

Consumer resources

• Hyton (Advanced Reading)

Other brands: Hyton

Professional resources

Related treatment guides

• ADHD

See also:
What is the most important information I should know about Hyton?

Hyton (Hyton) is contraindicated in patients with known hypersensitivity or idiosyncrasy to the drug. Hyton (Hyton) should not be administered to patients with impaired hepatic function.

See also:
What other drugs will affect Hyton?

The interaction of Hyton (Hyton) with other drugs has not been studied in humans. Patients who are receiving Hyton (Hyton) concurrently with other drugs, especially drugs with CNS activity, should be monitored carefully.

Decreased seizure threshold has been reported in patients receiving Hyton (Hyton) concomitantly with antiepileptic medications.

See also:
What are the possible side effects of Hyton?

The following are adverse reactions in decreasing order of severity within each category associated with Hyton (Hyton) :

Hepatic: There have been reports of hepatic dysfunction, ranging from asymptomatic reversible increases in liver enzymes to hepatitis, jaundice and life- threatening hepatic failure, in patients taking Hyton.

Hematopoietic: There have been isolated reports of aplastic anemia.

Central Nervous System: The following CNS effects have been reported with the use of Hyton (Hyton) : convulsive seizures: literature reports indicate that Hyton (Hyton) may precipitate attacks of Gilles de la Tourette syndrome; hallucinations; dyskinetic movements of the tongue, lips, face and extremities: abnorrnal oculomotor function including nystagmus and oculogyric crisis; mild depression; dizziness; increased irritability; headache; and drowsiness.

Insomnia is the most frequently reported side effect of Hyton (Hyton), it usually occurs early in therapy prior to an optimum therapeutic response. In the majority of cases it is transient in nature or responds to a reduction in dosage.

Gastrointestinal: Anorexia and weight loss may occur during the first weeks of therapy. In the majority of cases it is transient in nature; weight gain usually resumes within three to six months.

Nausea and stomach ache have also been reported.

Genitourinary: A case of elevated acid phosphatase in association with prostatic enlargement has been reported in a 63 year old male who was treated with Hyton (Hyton) for sleepiness. The acid phosphatase normalized with discontinuation of Hyton (Hyton) and was again elevated with rechallenge.

Miscellaneous: Suppression of growth has been reported with the long- term use of stimulants in children. Skin rash has been reported with Hyton (Hyton).

Mild adverse reactions appearing early during the course of treatment with Hyton (Hyton) often remit with continuing therapy. If adverse reactions are of a significant or protracted nature, dosage should be reduced or the drug discontinued.

DRUG ABUSE AND DEPENDENCE

Controlled Substance: Hyton (Hyton) is subject to control under DEA schedule IV.

Abuse: Hyton (Hyton) failed to demonstrate a potential for self- administration in primates. However, the pharmacologic similarity of Hyton to other psychostimulants with known dependence liability suggests that psychological and/ or physical dependence might also occur with Hyton (Hyton). There have been isolated reports of transient psychotic symptoms occurring in adults following the long- term misuse of excessive oral doses of Hyton. Hyton (Hyton) should be given with caution to emotionally unstable patients who may increase the dosage on their own initiative.